Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
- This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
- Spherix Global Insights recently published its seventh annual Patient Chart Dynamix™: Triggers and Drivers in Psoriatic Arthritis, (previously RealWorld Dynamix: Switching in Psoriatic Arthritis).
- Patients receiving TNFs are also provided an ample period of treatment in the first-line setting before considering a switch to an alternative therapy.
- Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.